Tanzania Cancer Immunotherapy Market Analysis
Tanzania's cancer immunotherapy market is expected to witness growth from $45 Mn in 2022 to $83 Mn in 2030 with a CAGR of 8% for the forecasted year 2022-30. The growing prevalence of cancer and increased healthcare expenditure in Tanzania is responsible for the growth of the market. The Tanzania cancer immunotherapy market is segmented by type, application, and end user. Tanga Pharmaceuticals, Moraf Pharmaceutical, and Amgen are the major players in the Tanzania cancer immunotherapy market.
Buy Now
Tanzania Cancer Immunotherapy Market Executive Analysis
Tanzania's cancer immunotherapy market is expected to witness growth from $45 Mn in 2022 to $83 Mn in 2030 with a CAGR of 8% for the forecasted year 2022-30. To meet Tanzania's expanding development needs, the government intends to boost spending by 4.4 % in the upcoming fiscal year. Finance and Planning Minister Mwigulu Nchemba stated that the government would spend $18 Bn in the fiscal year 2023–24, an increase from $17 Bn the previous year while presenting the principles for the creation of the government budget. The remaining $6.4 Bn would be allocated for development, leaving $12 Bn for recurring expenses. The additional funding would also be used to maintain health and educational programs, prepare for the 2024 local elections, and create a new National Development Vision for 2050.
Over the previous five years, cancer incidence has increased in Tanzania. Cancer is the second greatest cause of death for women and the fifth major cause of death for men in Tanzania, with the most prevalent malignancies being cervical carcinoma, breast cancer, prostate cancer, and other gynecological cancers. According to the Global Cancer Observatory, more than 10,000 women in Tanzania are diagnosed with cervical cancer each year.
Beyond their exceptional clinical success in select patients, immunotherapy using immune checkpoint modulators revolutionizes the area of oncology. A more comprehensive understanding of the cancer patient, it causes significant changes in the evaluation of therapeutic efficacy and toxicity. The development of T cell-targeted immunomodulators that block the immunological checkpoints CTLA-4 and PD1 or PDL1 has unquestionably been the greatest advancement in cancer treatment in the past ten years. The first antibody to suppress an immunological checkpoint (CTLA4), ipilimumab, was approved. Monoclonal antibodies that target PD1 (pembrolizumab and nivolumab) and PDL1 (atezolizumab and durvalumab) were quickly developed after this. Anti-PD1/PDL1 antibodies are among the most frequently given anticancer medications today. About 50 different cancer types are now being treated using T-cell-targeted immunomodulators as single medicines or in combination with chemotherapies.
Market Dynamics
Market Growth Drivers
Tanzania is experiencing an increasing problem with cancer, as the frequency of the disease has been rising quickly in recent years. Effective cancer treatments like immunotherapy are now more necessary than ever before as a result. Many people in Tanzania might not be aware of immunotherapy, a relatively new method of cancer treatment. However, when more patients become aware of the advantages of immunotherapy, they might consider it as a therapeutic option. Recent increases in healthcare spending by the Tanzanian government and other non-governmental organizations may result in more money being allocated to research and development of cancer immunotherapy leading to the growth of the Tanzania cancer immunotherapy market.
Market Restraints
Tanzania's healthcare system is still being developed, which may make it more difficult to offer effective cancer treatments, including immunotherapy. The number of possible patients for immunotherapy may be constrained in Tanzania because many individuals may not have access to medical facilities or may not be able to pay for cancer treatment. Tanzania has been attempting to enhance its regulatory environment, but there may still be a lack of adequate regulatory infrastructure to facilitate the creation and approval of cancer immunotherapy drugs, therefore, limiting the growth and expansion of Tanzania's cancer immunotherapy market.
Competitive Landscape
Key Players
- Shelys Pharmaceutical (TZA)
- Salama Pharmaceuticals (TZA)
- Zenufa Laboratories (TZA)
- Tanga Pharmaceuticals (TZA)
- Moraf Pharmaceutical (TZA)
- Amgen
- Bayer
- AstraZeneca
- Bristol-Myers Squibb
- F. Hoffmann-La Roche
- Pfizer
- Eli Lily
Healthcare Policies and Regulatory Landscape
Tanzania's National Health Insurance Fund (NHIF) offers its members coverage for cancer treatment. The majority of cancer treatments, such as chemotherapy, radiotherapy, and surgery, are covered by the NHIF; however, patients may be responsible for certain out-of-pocket costs, particularly for more complicated or expensive procedures. The NHIF uses a fee-for-service reimbursement approach, where healthcare practitioners are paid for the services, they render. Healthcare providers must adhere to fee schedules established by the NHIF for various medical operations, including cancer treatment. The full expense of cancer treatment, however, may not always be covered by reimbursement policies and price schedules, particularly for more cutting-edge or experimental therapies like immunotherapy. Patients may be required to pay out-of-pocket in such circumstances or request financial aid from non-governmental groups or other sources.
1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country
2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)
3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints
4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)
4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)
5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment
6. Methodology and Scope
Cancer Immunotherapy Segmentation
By Type (Revenue, USD Billion):
- Monoclonal Antibodies
- Cancer Vaccines
- Checkpoint Inhibitors
- Immunomodulators
- PD-1/PD-L1
- CTLA-4
By Application (Revenue, USD Billion):
- Lung Cancer
- Breast Cancer
- Head and Neck Cancer
- Prostate Cancer
- Colorectal Cancer
- Melanoma
- Others
By End User (Revenue, USD Billion):
- Hospitals
- Clinics
- Ambulatory Surgical Centers (ASCs)
- Cancer Research Centers
Methodology for Database Creation
Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.
Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.
How Do We Get It?
Our database is created and maintained through a combination of secondary and primary research methodologies.
1. Secondary Research
With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:
- Analyzing historical proprietary data collected from multiple projects.
- Regularly updating our existing data sets with new findings and trends.
- Ensuring data consistency and accuracy through rigorous validation processes.
With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:
- Searching through academic conferences, published research, citations, and social media platforms
- Collecting and compiling diverse data to build a comprehensive and detailed database
- Continuously updating our database with new information to ensure its relevance and accuracy
2. Primary Research
To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:
- Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
- Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
- Continuously refreshing our database to ensure that the information remains current and reliable.
- Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.
Combining Secondary and Primary Research
By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:
- Merging historical data from secondary research with real-time data from primary research.
- Conducting thorough data validation and cleansing to remove inconsistencies and errors.
- Organizing data into a structured format that is easily accessible and usable for various applications.
- Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.
Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.
To request a free sample copy of this report, please complete the form below.
We value your inquiry and offer free customization with every report to fulfil your exact research needs.
Tanga Pharmaceuticals, Moraf Pharmaceutical, and Amgen are the major players in the Tanzania cancer immunotherapy market.
The Tanzania cancer immunotherapy market is expected to grow from $45 Mn in 2022 to $83 Mn in 2030 with a CAGR of 8% for the forecasted year 2022-2030.
The Tanzania cancer immunotherapy market is segmented by type, application, and end user.
Related reports (by category)
Singapore Anti-Venom Market Analysis
Brazil Liver Cancer Drugs Market Analysis
France Topical Pain Relief Market Analysis
Related reports (by geography)
Tanzania Coronary Stents Market Analysis
Tanzania Palliative Care Market Analysis
